This article is more than 5 years old. Information may no longer be current.
Ticagrelor, clopidogrel yield similar outcomes in EUCLID trial
Click Here to Manage Email Alerts
Top-line results of the EUCLID trial did not demonstrate a benefit of ticagrelor over clopidogrel for prevention of atherothrombotic events in patients with symptomatic peripheral artery disease, according to a press release issued by AstraZeneca.
Full results from the EUCLID trial are slated for presentation at the American Heart Association Scientific Sessions in New Orleans in November.
EUCLID is the largest CV outcomes trial to data conducted exclusively in patients aged 50 years and older with symptomatic PAD (ankle-brachial index 0.80), according to the release. Researchers enrolled 13,885 patients in 28 countries worldwide. Patients were randomly assigned 1:1 to ticagrelor (Brilinta, AstraZeneca) 90 mg twice daily or clopidogrel 75 mg once daily. The primary endpoint was time to first occurrence of atherothrombotic events, defined as a composite of CV death, MI or ischemic stroke.
While ticagrelor did not meet the primary endpoint in the EUCLID trial, the safety data are consistent with the known safety profile of ticagrelor, according to the release.
“The proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are established and remain unchanged,” Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, stated in the release. “We are disappointed that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population.”
Disclosure: Bohen is chief medical officer at AstraZeneca.